Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000168277 | SCV000218949 | uncertain significance | Pancreatic adenocarcinoma | 2023-03-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 281 of the PALLD protein (p.Asp281Tyr). This variant is present in population databases (rs759105985, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. ClinVar contains an entry for this variant (Variation ID: 188290). |
Ambry Genetics | RCV004020004 | SCV002734871 | uncertain significance | not specified | 2021-06-26 | criteria provided, single submitter | clinical testing | The p.D768Y variant (also known as c.2302G>T), located in coding exon 12 of the PALLD gene, results from a G to T substitution at nucleotide position 2302. The aspartic acid at codon 768 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |